|
Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre |
Research Funding - Millennium (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - MSD Oncology; Pfizer |
|
|
Honoraria - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi |
Research Funding - Sanofi (Inst) |
|
|
Research Funding - Merck Sharp & Dohme; Roche/Genentech |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck; Roche |
Research Funding - Astellas Pharma |
Travel, Accommodations, Expenses - Roche |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai |
Research Funding - Bristol-Myers Squibb; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - Atreca; IDEAYA Biosciences; MIODx |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Nektar (Inst); Roche/Genentech (Inst) |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Pfizer; UpToDate |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals |
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi |
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Pfizer |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME |
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio |
Expert Testimony - Celgene; sanofi |
|
|
Honoraria - NCCN; UpToDate |
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech |
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |
Travel, Accommodations, Expenses - advisory boards/consultancy |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Roche |
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst) |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Sanofi |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi |
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Janssen; Roche |
Research Funding - Astellas Pharma; MSD; Roche |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen |
|
|
No Relationships to Disclose |
|
|
|
|
|
Employment - Aevi Genomic Medicine (I); Amicus Therapeutics (I); Merck |
Leadership - VenatoRx (I) |
Stock and Other Ownership Interests - AstraZeneca (I); GlaxoSmithKline (I); Merck |
Travel, Accommodations, Expenses - Aevi Genomic Medicine (I); Amicus Therapeutics (I); Merck |
|
|
Employment - Merck Sharp & Dohme |
Patents, Royalties, Other Intellectual Property - Perini |
|
|
Honoraria - Merck Sharp & Dohme |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma |